{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:56:09Z","timestamp":1777892169927,"version":"3.51.4"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p><jats:italic>De novo<\/jats:italic> immune responses to myeloid and other blood-borne tumors are notably limited and ineffective, making our ability to promote immune responses with vaccines a major challenge. While focus has been largely on cytotoxic cell-mediated tumor eradication, B-cells and the antibodies they produce also have roles in anti-tumor responses. Indeed, therapeutic antibody-mediated tumor cell killing is routinely employed in patients with hematolymphoid cancers, but whether endogenous antibody responses can be incited to blood-born tumors remains poorly studied. A major limitation of immunoglobulin therapies is that cell surface expression of tumor-associated antigen (TAA) targets is dynamic and varied, making promotion of polyclonal, endogenous B cell responses appealing. Since many TAAs are self-antigens, developing tumor vaccines that enable production of antibodies to non-polymorphic antigen targets remains a challenge. As B cell responses to RNA vaccines are known to occur, we employed the Viral Replicon Particles (VRP) which was constructed to encode mouse FLT3. The VRP-FLT3 vaccine provoked a rapid IgG B-cell response to this self-antigen in leukemia and lymphoma mouse models. In addition, IgGs to other TAAs were also produced. Our data suggest that vaccination with RNA viral particle vectors incites a loss of B-cell tolerance that enables production of anti-tumor antibodies. This proof of principle work provides impetus to employ such strategies that lead to a break in B-cell tolerance and enable production of broadly reactive anti-TAA antibodies as potential future therapeutic agents for patients with hematolymphoid cancers.<\/jats:p>","DOI":"10.3389\/fimmu.2022.865486","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T10:54:05Z","timestamp":1653389645000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Alphavirus Replicon Particle Vaccine Breaks B Cell Tolerance and Rapidly Induces IgG to Murine Hematolymphoid Tumor Associated Antigens"],"prefix":"10.3389","volume":"13","author":[{"given":"Hsuan","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel A.","family":"DiCioccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S.","family":"Serody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan C.","family":"Poe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benny J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phuong L.","family":"Doan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Sarantopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60251-8","article-title":"Monoclonal Antibodies for Cancer Immunotherapy","volume":"373","author":"Weiner","year":"2009","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2744","article-title":"Monoclonal Antibodies: Versatile Platforms for Cancer Immunotherapy","volume":"10","author":"Weiner","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04197.x","article-title":"Immunotherapy Prospects for Acute Myeloid Leukaemia","volume":"161","author":"Barrett","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.critrevonc.2015.08.014","article-title":"A Review of Monoclonal Antibody Therapies in Lymphoma","volume":"97","author":"Teo","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/cr.2016.154","article-title":"Driving Gene-Engineered T Cell Immunotherapy of Cancer","volume":"27","author":"Johnson","year":"2017","journal-title":"Cell Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer","volume":"9","author":"Mehta","year":"2018","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra072739","article-title":"Cancer Immunology","volume":"358","author":"Finn","year":"2008","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0733-4","article-title":"A Systematic Review of Humoral Immune Responses Against Tumor Antigens","volume":"58","author":"Reuschenbach","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41577-019-0257-x","article-title":"B Cells, Plasma Cells and Antibody Repertoires in the Tumour Microenvironment","volume":"20","author":"Sharonov","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/science.1086907","article-title":"Predominant Autoantibody Production by Early Human B Cell Precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI10196","article-title":"Detection of a Potent Humoral Response Associated With Immune-Induced Remission of Chronic Myelogenous Leukemia","volume":"106","author":"Wu","year":"2000","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.131590998","article-title":"CML66, a Broadly Immunogenic Tumor Antigen, Elicits a Humoral Immune Response Associated With Remission of Chronic Myelogenous Leukemia","volume":"98","author":"Yang","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"B13","article-title":"CML28 Is a Broadly Immunogenic Antigen, Which Is Overexpressed in Tumor Cells","volume":"62","author":"Yang","year":"2002","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-211375","article-title":"Antibodies Specifically Target AML Antigen Nusap1 After Allogeneic Bone Marrow Transplantation","volume":"115","author":"Wadia","year":"2010","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.cell.2017.07.026","article-title":"Clonal Evolution of Autoreactive Germinal Centers","volume":"170","author":"Degn","year":"2017","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-021-01311-z","article-title":"Mrna Vaccine: A Potential Therapeutic Strategy","volume":"20","author":"Wang","year":"2021","journal-title":"Mol Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1006\/viro.1997.8878","article-title":"Replicon-Helper Systems From Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genes In Vitro and Immunization Against Heterologous Pathogens In Vitro","volume":"239","author":"Pushko","year":"1997","journal-title":"Virology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.2.914-922.2000","article-title":"Role of Dendritic Cell Targeting in Venezuelan Equine Encephalitis Virus Pathogenesis","volume":"74","author":"MacDonald","year":"2000","journal-title":"J Virol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.360","article-title":"Alphavirus Vectors and Vaccination","volume":"12","author":"Rayner","year":"2002","journal-title":"Rev Med Virol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/v6062392","article-title":"Alphavirus-Based Vaccines","volume":"6","author":"Lundstrom","year":"2014","journal-title":"Viruses"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.030","article-title":"Infected Dendritic Cells Are Sufficient to Mediate the Adjuvant Activity Generated by Venezuelan Equine Encephalitis Virus Replicon Particles","volume":"30","author":"Tonkin","year":"2012","journal-title":"Vaccine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.1.371-378.2000","article-title":"Vaccination of Macaques Against Pathogenic Simian Immunodeficiency Virus With Venezuelan Equine Encephalitis Virus Replicon Particles","volume":"74","author":"Davis","year":"2000","journal-title":"J Virol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.06.058","article-title":"Alphaviral Vector-Transduced Dendritic Cells Are Successful Therapeutic Vaccines Against Neu-Overexpressing Tumors in Wild-Type Mice","volume":"25","author":"Moran","year":"2007","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1023\/B:BREA.0000004373.09678.bb","article-title":"Venezuelan Equine Encephalitis Replicon Immunization Overcomes Intrinsic Tolerance and Elicits Effective Anti-Tumor Immunity to the \u2018Self\u2019 Tumor-Associated Antigen, Neu in a Rat Mammary Tumor Model","volume":"82","author":"Nelson","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9517-8","article-title":"VRP Immunotherapy Targeting Neu: Treatment Efficacy and Evidence for Immunoediting in a Stringent Rat Mammary Tumor Model","volume":"106","author":"Laust","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181d756bb","article-title":"The Immunosuppressive Tumor Environment Is the Major Impediment to Successful Therapeutic Vaccination in Neu Transgenic Mice","volume":"33","author":"Burgents","year":"2010","journal-title":"J Immunother"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/bcr962","article-title":"Alphavirus Replicon Particles Containing the Gene for HER2\/Neu Inhibit Breast Cancer Growth and Tumorigenesis","volume":"7","author":"Wang","year":"2005","journal-title":"Breast Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1410","article-title":"Comparison of Two Cancer Vaccines Targeting Tyrosinase: Plasmid DNA and Recombinant Alphavirus Replicon Particles","volume":"11","author":"Goldberg","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012670","article-title":"Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma Through Activation of Humoral and Cellular Immunity","volume":"5","author":"Avogadri","year":"2010","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2996","article-title":"In Vivo Effects of Vaccination With Six-Transmembrane Epithelial Antigen of the Prostate: A Candidate Antigen for Treating Prostate Cancer","volume":"67","author":"Garcia-Hernandez","year":"2007","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1158\/1078-0432.CCR-06-2202","article-title":"A Novel Alphavirus Vaccine Encoding Prostate-Specific Membrane Antigen Elicits Potent Cellular and Humoral Immune Responses","volume":"13","author":"Durso","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.11.096","article-title":"A Phase I Dose Escalation Trial of Vaccine Replicon Particles (VRP) Expressing Prostate-Specific Membrane Antigen (PSMA) in Subjects With Prostate Cancer","volume":"31","author":"Slovin","year":"2013","journal-title":"Vaccine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, Double-Blind, Phase 1 Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus in CMV Seronegative Adult Volunteers","volume":"28","author":"Bernstein","year":"2009","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI42672","article-title":"An Alphavirus Vector Overcomes the Presence of Neutralizing Antibodies and Elevated Numbers of Tregs to Induce Immune Responses in Humans With Advanced Cancer","volume":"120","author":"Morse","year":"2010","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3102","article-title":"Vaccine-Induced Memory CD8(+) T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study","volume":"25","author":"Crosby","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001662","article-title":"Long-Term Survival of Patients With Stage III Colon Cancer Treated With VRP-CEA(6D), an Alphavirus Vector That Increases the CD8+ Effector Memory T Cell to Treg Ratio","volume":"8","author":"Crosby","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0600287103","article-title":"Mucosal and Systemic Adjuvant Activity of Alphavirus Replicon Particles","volume":"103","author":"Thompson","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.02.010","article-title":"Alphavirus Replicon-Based Enhancement of Mucosal and Systemic Immunity Is Linked to the Innate Response Generated by Primary Immunization","volume":"28","author":"Tonkin","year":"2010","journal-title":"Vaccine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00327-14","article-title":"An Alphavirus-Based Adjuvant Enhances Serum and Mucosal Antibodies, T Cells, and Protective Immunity to Influenza Virus in Neonatal Mice","volume":"88","author":"Khalil","year":"2014","journal-title":"J Virol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00775","article-title":"TLR7\/TLR9- and B Cell Receptor-Signaling Crosstalk: Promotion of Potentially Dangerous B Cells","volume":"8","author":"Suthers","year":"2017","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402425","article-title":"Cell-Intrinsic Expression of TLR9 in Autoreactive B Cells Constrains BCR\/TLR7-Dependent Responses","volume":"194","author":"Nundel","year":"2015","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.07.007","article-title":"Targeting FLT3 for the Treatment of Leukemia","volume":"45","author":"Small","year":"2008","journal-title":"Semin Hematol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 Mutations in AML: Review of Current Knowledge and Evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.05.046","article-title":"Alphavirus Replicon Particles Acting as Adjuvants Promote CD8+ T Cell Responses to Co-Delivered Antigen","volume":"26","author":"Thompson","year":"2008","journal-title":"Vaccine"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008040","article-title":"BAFF Promotes Heightened BCR Responsiveness and Manifestations of Chronic GVHD After Allogeneic Stem Cell Transplantation","volume":"137","author":"Jia","year":"2021","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122430","article-title":"SYK Inhibitor Entospletinib Prevents Ocular and Skin GVHD in Mice","volume":"3","author":"Poe","year":"2018","journal-title":"JCI Insight"},{"key":"B47","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0165-2478(01)00239-5","article-title":"Differential Expression of GL7 Activation Antigen on Bone Marrow B Cell Subpopulations and Peripheral B Cells","volume":"78","author":"Cervenak","year":"2001","journal-title":"Immunol Lett"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20122798","article-title":"Overexpression of TLR7 Promotes Cell-Intrinsic Expansion and Autoantibody Production by Transitional T1 B Cells","volume":"210","author":"Giltiay","year":"2013","journal-title":"J Exp Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"827254","DOI":"10.1155\/2013\/827254","article-title":"B Lymphocytes: Development, Tolerance, and Their Role in Autoimmunity-Focus on Systemic Lupus Erythematosus","volume":"2013","author":"Tobon","year":"2013","journal-title":"Autoimmune Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2693","article-title":"Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases","volume":"71","author":"Corbiere","year":"2011","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw261","article-title":"Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment","volume":"109","author":"Gulley","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"B52","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1182\/blood-2011-01-325266","article-title":"Autoimmunity Associated With Immunotherapy of Cancer","volume":"118","author":"Amos","year":"2011","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1248-y","article-title":"Co-Delivery of Antigen and IL-12 by Venezuelan Equine Encephalitis Virus Replicon Particles Enhances Antigen-Specific Immune Responses and Antitumor Effects","volume":"61","author":"Osada","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0220","article-title":"Combination of Alphavirus Replicon Particle-Based Vaccination With Immunomodulatory Antibodies: Therapeutic Activity in the B16 Melanoma Mouse Model and Immune Correlates","volume":"2","author":"Avogadri","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.05.010","article-title":"Excess BAFF Rescues Self-Reactive B Cells From Peripheral Deletion and Allows Them to Enter Forbidden Follicular and Marginal Zone Niches","volume":"20","author":"Thien","year":"2004","journal-title":"Immunity"},{"key":"B56","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.coviro.2017.11.006","article-title":"Innate Immune Control of Alphavirus Infection","volume":"28","author":"Carpentier","year":"2018","journal-title":"Curr Opin Virol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050630","article-title":"RNA-Associated Autoantigens Activate B Cells by Combined B Cell Antigen Receptor\/Toll-Like Receptor 7 Engagement","volume":"202","author":"Lau","year":"2005","journal-title":"J Exp Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-668145","article-title":"Antibodies From Donor B Cells Perpetuate Cutaneous Chronic Graft-Versus-Host Disease in Mice","volume":"127","author":"Jin","year":"2016","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-364414","article-title":"Donor B-Cell Alloantibody Deposition and Germinal Center Formation are Required for the Development of Murine Chronic GVHD and Bronchiolitis Obliterans","volume":"119","author":"Srinivasan","year":"2012","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3660","article-title":"Antibody Responses to H-Y Minor Histocompatibility Antigens Correlate With Chronic Graft-Versus-Host Disease and Disease Remission","volume":"105","author":"Miklos","year":"2005","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bbmt.2014.10.029","article-title":"B Cells in Chronic Graft-Versus-Host Disease","volume":"21","author":"Sarantopoulos","year":"2015","journal-title":"Biol Blood Mar Transplant"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-567834","article-title":"Aberrant B-Cell Homeostasis in Chronic GVHD","volume":"125","author":"Sarantopoulos","year":"2015","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.865486\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T10:54:08Z","timestamp":1653389648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.865486\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":62,"alternative-id":["10.3389\/fimmu.2022.865486"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.865486","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]},"article-number":"865486"}}